ArticleCureus2025
The Effect of Latent Hepatitis B Infection on Autoimmune Hepatitis Treatment Outcomes.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to determine how latent hepatitis B virus (HBV) infection affects the treatment response and disease progression in patients with autoimmune hepatitis (AIH). We retrospectively analyzed clinical and laboratory data from 36 hepatitis B surface antigen (HBsAg)-negative AIH patients, classified based on anti-HBc immunoglobulin G (IgG) status to identify latent HBV presence. Among these, 13 patients (36.1%) were anti-HBc IgG-positive, indicating latent HBV infection, while 23 patients (63.9%) were negative. Liver function markers were assessed at diagnosis and after one year of standard immunosuppressive therapy to determine treatment response. Our results indicate that patients harboring latent HBV exhibit a poorer biochemical response to AIH treatment, with persistently elevated liver enzymes and impaired liver function markers compared to those without latent infection. These findings highlight the potential impact of latent HBV on disease progression and treatment efficacy in AIH. We therefore recommend comprehensive screening for latent HBV in all AIH patients before immunosuppressive therapy and consideration of antiviral prophylaxis to improve therapeutic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.